The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
Open accessAbstract
Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed world. Evidence increasingly shows that these conditions are interlinked through common risk factors, coincident in an ageing population, and are connected biologically through some deleterious effects of anticancer treatment on CV health. Anticancer therapies can cause a wide spectrum of short- and long-term cardiotoxic effects. An explosion of novel cancer therapies has revolutionised this field and dramatically altered cancer prognosis. Nevertheless, these new therapies have introduced unexpected CV complications beyond heart failure. Common CV toxicities related to cancer therapy are defined, along with suggested strategies for prevention, detection and treatment. This ESMO consensus article proposes to define CV toxicities related to cancer or its therapies and provide guidance regarding prevention, screening, monitoring and treatment of CV toxicity. The majority of anticancer therapies are associated with some CV toxicity, ranging from asymptomatic and transient to more clinically significant and long-lasting cardiac events. It is critical however, that concerns about potential CV damage resulting from anticancer therapies should be weighed against the potential benefits of cancer therapy, including benefits in overall survival. CV disease in patients with cancer is complex and treatment needs to be individualised. The scope of cardio-oncology is wide and includes prevention, detection, monitoring and treatment of CV toxicity related to cancer therapy, and also ensuring the safe development of future novel cancer treatments that minimise the impact on CV health. It is anticipated that the management strategies discussed herein will be suitable for the majority of patients. Nonetheless, the clinical judgment of physicians remains extremely important; hence, when using these best clinical practices to inform treatment options and decisions, practitioners should also consider the individual circumstances of their patients on a case-by-case basis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to the cumulative cisplatin dose, peak drug exposure, young age at treatment, co-administration of other ototoxic drugs and others are well-defined risk factors for more severe auditory damage 167,168,169 .”
From Osteosarcoma (2022) · cites this paper as [167]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–221 of 221
Ammon, M., Arenja, N., Leibundgut, G., Buechel, R. R., Kuster, G. M., Kaufmann, B. A., & Pfister, O. (2013) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2013.07.007 · Cited by 44
Naing, A., Rodrigues, H. V., Hong, D. S., Fu, S., Falchook, G. S., Wheler, J. J., Tsimberidou, A. M., Wen, S., Fessahaye, S. N., Golden, E. C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds130 · Cited by 44
Chuy, K. L., Oikonomou, E. K., Postow, M. A., Callahan, M. K., Chapman, P. B., Shoushtari, A. N., Neilan, T. G., Fradley, M. G., Ramanathan, L. V., Wolchok, J. D., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0040 · Cited by 44
Self-citationMeléndez, G. C., Sukpraphrute, B., D'Agostino, R. B., Jordan, J. H., Klepin, H. D., Ellis, L. R., Lamar, Z. S., Vasu, S., Lesser, G. J., Burke, G. L., et al. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.02.008 · Cited by 43
Catino, A. B., Hubbard, R. A., Chirinos, J. A., Townsend, R. R., O’Keefe, S. J., Haas, N. B., Puzanov, I. J., Fang, J. C.-T., Agarwal, N., Hyman, D. M., et al. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004408 · Cited by 43
Self-citationCurigliano, G., Spitaleri, G., Fingert, H. J., de Braud, F., Sessa, C., Loh, E. Y., Cipolla, C. M., Pas, T. M. D., Goldhirsch, A., & Shah, R. R. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.10.001 · Cited by 42
Self-citationBiomarkers as Predictors of Cardiac Toxicity From Targeted Cancer Therapies
Witteles, R. M. (2016) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2016.03.016 · Cited by 37
Self-citationVerma, S., & Ewer, M. S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq607 · Cited by 36
Leger, K. J., Baker, K. S., Cushing‐Haugen, K. L., Flowers, M. E. D., Leisenring, W. M., Martin, P. J., Mendoza, J. A., Reding, K. W., Syrjala, K. L., Lee, S. J., et al. (2018) · Cancer · doi:10.1002/cncr.31227 · Cited by 33
Ky, B., & Carver, J. R. (2011) · Heart Failure Clinics · doi:10.1016/j.hfc.2011.03.002 · Cited by 31
Self-citationYu, A. F., Yadav, N., Eaton, A. A., Lung, B. Y., Thaler, H. T., Liu, J. E., Hudis, C. A., Dang, C. T., & Steingart, R. M. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0125 · Cited by 30
New Era in Radiation Oncology for Lung Cancer: Recognizing the Importance of Cardiac Irradiation
Simone, C. B. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.5581 · Cited by 24
Tall, A. R., & Levine, R. L. (2017) · Nature · doi:10.1038/nature21505 · Cited by 24
Stoodley, P. W., Richards, D. A. B., Meikle, S. R., Clarke, J., Hui, R., & Thomas, L. (2010) · Heart Lung and Circulation · doi:10.1016/j.hlc.2010.09.007 · Cited by 22
Ganatra, S., & Hayek, S. S. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.05.008 · Cited by 21
Self-citationCopeland, K. A., Hosmane, V. R., Jurkovitz, C. T., Kolm, P., Bowen, J., DiSabatino, A., Banbury, M. K., Strasser, J. F., Weintraub, W. S., & Doorey, A. J. (2013) · Clinical Cardiology · doi:10.1002/clc.22106 · Cited by 20
Cardiovascular Safety Monitoring During Oncology Drug Development and Therapy
Turner, J. R., Panicker, G. K., Karnad, D. R., Cabell, C. H., Lieberman, R., & Kothari, S. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000027 · Cited by 13
ABCDE Steps for Heart and Vascular Wellness Following a Prostate Cancer Diagnosis
Guan, J., Khambhati, J., Jones, L. W., Morgans, A. K., Allaf, M. E., Penson, D. F., & Moslehi, J. J. (2015) · Circulation · doi:10.1161/circulationaha.115.012521 · Cited by 12
Self-citationReporting of immune checkpoint inhibitor-associated myocarditis – Authors' reply
Moslehi, J. J., Salem, J., Sosman, J. A., Lebrun‐Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31556-3 · Cited by 10
Self-citationEffect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials
Borad, M. J., Soman, A. D., Benjamin, M., Casa, D., Tembe, W., Piper, B. F., Ramanathan, R. K., Tibes, R., Jameson, G., Ansaldo, K., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9909-4 · Cited by 9
Burke, L. M. B., Bashir, M. R., Neville, A. M., Nelson, R. C., & Jaffe, T. A. (2013) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2013.08.018 · Cited by 9
Cited by
Sorted by citations
Lyon, A. R., López‐Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J. K., Boriani, G., Cardinale, D. M., Córdoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,457
Self-citationTargeting HER2-positive breast cancer: advances and future directions
Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Loibl, S., André, F., Bachelot, T., Barrios, C. H., Bergh, J. C. S., Burstein, H. J., Cardoso, M. J., Carey, L., Dawood, S. S., Mastro, L. D., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.11.016 · Cited by 1,135
Self-citationBeird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Herrmann, J., Lenihan, D. J., Armenian, S. H., Barac, A., Blaes, A. H., Cardinale, D. M., Carver, J. R., Dent, S. F., Ky, B., Lyon, A. R., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab674 · Cited by 699
Self-citation
Metadata
- Authors
- Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M. G., Orecchia, R., de Azambuja, E., Zamorano, J. L., Krone, R., Iakobishvili, Z., Carver, J., Armenian, S., Ky, B., Cardinale, D., Cipolla, C. M., Dent, S., & Jordan, K.
- Affiliations
- University of Milan (IT)
- Washington University Medical Center (US)
- University of South Florida (US)
- Lahey Hospital and Medical Center (US)
- Georgetown University (US)
- University of Minnesota (US)
- Mayo Clinic (US)
- University of Kansas Medical Center (US)
- Royal Brompton Hospital (GB)
- Centre Hospitalier Universitaire de Liège (BE)
- University of Chicago (US)
- Vanderbilt University (US)
- Stanford Medicine (US)
- European Institute of Oncology (IT)
- Hospital Universitario Ramón y Cajal (ES)
- Washington University in St. Louis (US)
- Tel Aviv University (IL)
- Hospital of the University of Pennsylvania (US)
- City Of Hope National Medical Center (US)
- University of Pennsylvania (US)
- Duke University (US)
- Heidelberg University (DE)
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 31
- Issue
- 2
- Pages
- 171-190
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC8019325
- OpenAlex
- W2999536665
- Cited by
- 1,031
- References
- 221
- Citations by year
- 2026: 108 · 2025: 152 · 2024: 168 · 2023: 189 · 2022: 188 · 2021: 143 · 2020: 83
- FWCI
- 93.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- HF
- Genentech
- Amgen
- Servier
- Pfizer
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
- Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
- Keywords
- cardio-oncology, cardiotoxicity, cancer therapy, heart failure, cardiovascular screening, cardiovascular monitoring, novel cancer therapies, cardiovascular disease in cancer patients
- MeSH terms
- Antineoplastic Agents, Heart Diseases, Humans, Medical Oncology, Neoplasms, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
